Company Snapshot: Paratek Pharmaceuticals
Paratek Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon its expertise in novel tetracycline chemistry. The company’s lead product candidate, Omadacycline, is a novel investigational antibiotic with both once-daily intravenous (IV) and oral formulations for the treatment of community-acquired bacterial pneumonia (CABP), acute bacterial skin and skin structure infections (ABSSSI), and urinary tract infections (UTI). A modernized tetracycline, omadacycline is specifically designed to overcome tetracycline resistance and exhibits activity across a broad spectrum of bacteria, including Gram-positive, Gram-negative, anaerobes, atypical bacteria, and other drug-resistant strains.
- Oct 17 2019 Paratek Withdraws European Marketing Authorization Application for Oral and Intravenous NUZYRA in Skin Infections and Pneumonia
- Oct 1 2019 Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
- Sep 25 2019 Paratek Pharmaceuticals Presenting New Data from NUZYRA® (Omadacycline) Development Program at IDWeek 2019
- Sep 9 2019 Paratek Mourns Passing of Co-founder Dr. Stuart Levy